

Activation of the *met* Proto-oncogene in a Human Cell Line *

M. Dean¹, M. Park¹, K. Kaul¹, D. Blair², and G. F. Vande Woude¹

The *met* oncogene was identified in the MNNG-HOS cell line, derived by extensive treatment of a human osteosarcoma cell line (HOS) with *N*-methyl-*N*-*N'*-nitrosoguanidine (MNNG) [1]. DNA from MNNG-HOS cells was used to transform NIH/3T3

mouse fibroblast cells, and the transforming gene (*met*) was isolated from one of these NIH/3T3 transformants [2] (Fig. 1 a).

The activated *met* allele in MNNG-HOS cells is rearranged with sequences from another gene (Fig. 1). This second gene appears to provide the promoter for the activated *met* oncogene and has been named *tpr* for "translocated promoter region" [3]. The *tpr* locus has been mapped by somatic cell hybridization analysis to human chromosome 1 [3], whereas *met* mapped to chromosome 7 [2, 4]. Therefore, the *met* oncogene has been activated by a DNA rearrangement involving portions of chromosomes 1 and 7.

We examined the expression of the *met* and *tpr* sequences in HOS, MNNG-HOS, and transformed NIH/3T3 cells. As shown

¹ BRI-Basic Research Program, NCI-Frederick Cancer Research Facility, Frederick, Maryland

² Laboratory of Molecular Oncology, National Cancer Institute, Frederick, Maryland, USA

* Research sponsored by the National Cancer Institute, DHHS, under Contract NO. NO1-CO-23909 with Bionetics Research, Inc. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.




Fig. 1. Diagram of the *met* oncogene rearrangement. HOS cells treated with MNNG gave rise to MNNG-HOS cells. DNA from MNNG-HOS

cells is capable of morphologically transforming mouse NIH/3T3 cells, and the *tpr-met* gene was isolated from a transformant

Table 1. *met* and *tpr* mRNA species

Probe	Size of mRNA species ^a (kb) in		
	HOS cells	MNNG-HOS cells	NIH/3T3 trans-formants
<i>met</i>	9.0, 7.0, 6.0	9.0, 7.0, 6.0	—
<i>tpr-met</i>	—	5.0	5.0
<i>tpr</i>	10.0	10.0	—

^a mRNA species were determined by RNA blot hybridization, using *met* and *tpr* DNA as probes.

in Table 1, analysis with a *tpr* probe revealed an mRNA species of 10 kb in both HOS and MNNG-HOS cells. HOS and MNNG-HOS cells expressed *met* mRNAs of 9, 7 and 6 kb. However, analysis with probes from the 3' end of the *met* gene and the 5' end of *tpr* detected a hybrid 5.0-kb *tpr-met* transcript in MNNG-HOS cells [3] (Table 1), which is also found in NIH/3T3 cells transformed by MNNG-HOS DNA. We conclude that the gene rearrangement that activated the *met* locus results in the appearance of a hybrid mRNA transcript.

To determine the structure of the *met* gene product, we have begun to determine the nucleotide sequence of the coding regions. We have published the sequence of several *met* exons and demonstrated that *met* exhibits homology with the tyrosine kinase family of oncogenes and growth factor receptors [4]. We have recently isolated several *met* cDNA

clones from a library prepared from A431 human squamous cell carcinoma cells. The longest clone obtained was 1.6 kb, and when the nucleotide sequence was translated, the sequence was found to contain a single, long, open reading frame. Figure 2 shows the *met* sequence in one-letter amino acid code and compares it with several other tyrosine kinase genes.

The *met* gene is most extensively homologous to the human insulin receptor gene [5] and the *v-abl* oncogene from Abelson murine leukemia virus [6]. The homology is mostly confined to the kinase domain of the proteins and reaches 50%–60% at the amino acid level. However, the carboxy terminus of *met* is significantly different from that of the other members of the family. Therefore, although *met* is homologous to the tyrosine kinases, it is not identical to any other known member of that gene family.

Previous studies mapped the rearrangement of the *tpr-met* gene to a 3.4-kb *EcoRI* fragment [3]. To determine the nucleotide sequence of the breakpoint, we used *met* and *tpr* probes flanking the site of rearrangement to screen a λ phage library of human placental DNA. The rearrangement was mapped to small fragments present in the placental *met* and *tpr* phage clones. These fragments and a portion of *tpr-met* were cloned into M13 vectors and the nucleotide sequence was determined.

Figure 3 shows a portion of a sequencing gel of the *tpr* and *tpr-met* genes surrounding the chromosomal breakpoint. The se-




Fig. 2. Amino acid comparison of *met* with several protein kinases. The kinase domain of *met* is compared with the homologous region of the human

insulin receptor (HuIns^R), viral *abl* gene, *erbB/epidermal growth factor receptor*, viral *src* and *mos* genes




Fig. 3. Portion of a nucleotide-sequencing gel showing the *tpr-met* breakpoint. C, cytosine; G, guanine; T, thymine; A, adenine

quences of the *met* proto-oncogene and the *tpr-met* oncogene are identical through a stretch of 21 A residues. When the *tpr* sequence was used to search the NIH nucleotide data base, the sequence was shown to contain a member of the *Alu* family of highly repetitive sequences. These repeats are often followed by poly A-rich stretches, and the one in *tpr* is localized just upstream from the 21 A residues at the breakpoint. Therefore, the DNA rearrangement leading to the ac-




Fig. 4. Structure of the *tpr-met* breakpoint. Schematic of the rearrangement showing the position of the *Alu* repetitive element, 21 A residues, and the A-T-rich region flanking the breakpoint

tivation of *met* is located within this A-T rich region at the end of an *Alu* repeat.

Figure 4 is a schematic diagram of the *met* breakpoint region. The *met* and *tpr-met* genes are identical beyond the breakpoint for 600 residues, except for a single point mutation (not shown). Beyond the rearrangement site, on the *tpr* gene, is a stretch of 120 residues that are 80% A-T rich. Although chromosomal rearrangements have been observed in a wide variety of malignant cells [7], to our knowledge, this is the first time a chromosomal breakpoint has been sequenced in a nonhematopoietic cell. The nucleotide sequences of several other breakpoint sites have been determined and include rearranged *c-myc*, immunoglobulin heavy and light chain genes [8, 9], *bcll* [10], and T-cell receptor genes [11]; however, many of these rearrangements involve immunoglobulin switch-region sequences [8, 10] and are probably restricted to lymphoid cells. Our determination of the *tpr-met* chromosomal rearrangement also represents the first sequencing of a breakpoint isolated from a chemically transformed human cell.

The presence of an A-rich tract at the breakpoint suggests that these sequences may have played a role in the rearrangement. The rearrangement appears to be illegitimate because it occurred in a region with only four homologous nucleotides between *tpr* and *met* (Fig. 4 a). MNNG is clastogenic [12] and may have created a free end in either *met* or *tpr*, which would promote rearrangement. Alternatively, the A-T-rich region of *tpr* may have contributed to the rearrangement. These regions may exist in a single-stranded structure and may be more suscep-

tible to cleavage. Chromosomal regions with increased lability (fragile sites) have been described previously and have been proposed as playing a role in chromosomal rearrangement [13]. In fact, many fragile sites are induced by agents that interfere with thymidine metabolism [12]. It will be interesting to see whether *tpr* maps to any of the fragile sites located on chromosome 1.

The MNNG-HOS cell line used in our study arose after 7 days of MNNG treatment to HOS cells [1]. We cannot be sure that MNNG participated in the *tpr-met* rearrangement, but it is an interesting possibility. The principal action of MNNG on double-stranded DNA is the methylation of the N-7 position of guanine [14]. A pair of G residues is located in *tpr* just 3' to the breakpoint (not shown). MNNG is also capable of methylating adenine [14]; thus, MNNG-induced modification of residue(s) at the breakpoint may have contributed to the rearrangement. Besides the breakpoint, the only other change detected between *tpr-met* and placental DNA is a G-to-T transition. This alteration could be a polymorphic difference between individuals, could have arisen during transfection or cloning, or could have occurred as a consequence of MNNG treatment. At any rate, it is clear that massive mutation of the *tpr-met* gene did not occur in MNNG-HOS cells.

The expression of a truncated tyrosine kinase domain appears to be a common activation mechanism for this family of oncogenes. In addition to *tpr-met*, rearranged *bcr-abl* and *trk* genes have been isolated from human tumor DNA [15, 16]. Furthermore, retroviral insertion within the chicken epidermal growth factor receptor results in the expression of a truncated (*erbB*) kinase activity [17]. We are currently investigating the role, if any, of the *tpr* sequences in the transforming ability of the *tpr-met* oncogene.

The human *met* oncogene is located on a portion of chromosome 7 associated with nonrandom deletion in secondary acute nonlymphocytic leukemia patients [18]. Although we have not found any direct evidence of the fact that *met* plays a role in acute nonlymphocytic leukemia, an interesting outcome of that work is the discovery that *met* is very tightly linked to the gene for

cystic fibrosis [19]. Cystic fibrosis is a recessive genetic disorder characterized by abnormal exocrine gland function. Cells from patients with cystic fibrosis show abnormal regulation of chloride ion transport and impaired secretion in response to β -adrenergic agents (inducers of adenylate cyclase). Although it may seem unlikely that *met* is involved in this pathway, several proto-oncogenes appear to be involved in signal transmission [20]. Recent evidence suggests that chloride channels can be phosphorylated by a tyrosine kinase [21] and that tyrosine kinases can cooperate with adenylate cyclase to modulate gene expression [22]. Clearly, the tyrosine gene family plays important roles in the cellular control of growth, differentiation, and metabolism.

References

1. Rhim JS, Park DK, Arnstein P, Heubner RJ, Weisburger EK (1975) *Nature* 256:751-753
2. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF (1984) *Nature* 311:29-33
3. Park M, Dean M, Cooper CS, Schmidt M, O'Brien SJ, Blair DG, Vande Woude GF (1986) *Cell* 45:895-904
4. Dean M, Park M, LeBeau M, Robins T, Diaz M, Rowley J, Blair D, Vande Woude GF (1985) *Nature* 318:385-388
5. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao Y-C, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J (1985) *Nature* 313:756-761
6. Reddy EP, Smith MJ, Srinivasan A (1983) *Proc Natl Acad Sci USA* 3623-3627
7. Yunis JJ (1983) *Science* 221:227-236
8. Calame K, Kim S, Lalley P, Hill R, Davis M, Hood L (1982) *Proc Natl Acad Sci USA* 99:6994-6998
9. Neuberger MS, Calabi F (1983) *Nature* 305:240-243
10. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM (1985) *Nature* 315:340-343
11. Denny CT, Yoshika Y, Mak TW, Smith SD, Hollis GF, Kirsch IR (1986) *Nature* 320:549-551
12. Perry P, Evans HJ (1975) *Nature* 258:121-125
13. LeBeau MM (1986) *Blood* 67:849-858
14. Lawley PD, Thatcher CJ (1970) *Biochem J* 116:693-707

15. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) *Nature* 315:550–553
16. Martin-Zanca D, Hughes SH, Barbacid M (1986) *Nature* 319:743–748
17. Yamamoto T, Nishida T, Miyajima N, Kawai S, Ooi T, Toyoshima K (1983) *Cell* 35:71–78
18. Yunis J (1984) *Cancer Genet Cytogenet* 11:125–137
19. White R, Woodward S, Leppert M, O'Connell P, Hoff M, Herbst J, Lalouel J, Dean M, Vande Woude GF (1985) *Nature* 318:382–384
20. Bishop JM (1985) *Cell* 42:23–28
21. Mohamed AH, Stekk TL (1986) *J Biol Chem* 261:2804–2809
22. Ran W, Dean M, Campisi J (1986) *Proc Natl Acad Sci USA* 83:8216–8220